“Targeting RUNX1 Germline Variants: Agents Under Investigation.”Ghalamkari S, Hahn CN, Lau A, et al. Curr Hematol Malig Rep 2025.
“Successful venetoclax and azacitidine treatment in pediatric acute myeloid leukemia associated with familial platelet disorder.”Tsukamoto R, Nishio S, Saida S, et al. Pediatr Int 2025.
“RUNX1-FPDMM in families with mild thrombocytopenia and platelet function anomalies: a case series.”Glonnegger H, Boeckelmann D, Wiedenhöfer R, et al. Front Med 2025.
“TNF-α signaling drives myeloid skewing and clonal expansion of stem and progenitors in RUNX1-familial platelet disorder.”Mohammadhosseini M, Sahasrabudhe A, Ostrowski LH, et al. Haematologica 2025. [Early view]
“Closing the loop: Teaching single-cell foundation models to learn from perturbations.”Pershad Y, Nandi TN, Van Amburg JC, et al. bioRxiv 2025. [Preprint]
“Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy.”Liu J, Tran D, Xue L, et al. Nat Genet 2025.
“Pregnancy and delivery outcomes in individuals with RUNX1-Familial Platelet Disorder.”Deuitch NT, Haizler-Cohen L, Kajdic A, et al. Br J Haematol 2025.
“Examining the Effects of the RUNX1 p.Leu43Ser Variant on FPD/AML Phenotypes Using a CRISPR/Cas9-Generated Knock-In Murine Model.”Marin-Quilez A, García-Tuñón I, Benito R, et al. Biomolecules 2025.
“Germline copy number variants in RUNX1: An updated case report and a decade-old red herring.”Deuitch NT, Kajdic A, Bresciani E, et al. BJC Rep 2025.
“Disease characteristics and outcomes of acute myeloid leukemia in germline RUNX1 deficiency (Familial Platelet Disorder with associated Myeloid Malignancy).”Ernst MPT, Versluis J, Valk PJM, et al. HemaSphere 2025.
“Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1-familial platelet disorder.”Mohammadhosseini M, Enright T, Duvall A, et al. Sci Transl Med 2025.
